UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting the AKT protein kinase for cancer chemoprevention

Molecular cancer therapeutics, 2007-08, Vol.6 (8), p.2139-2148

2007

Volltextzugriff (PDF)

Energy homeostasis and cancer prevention: the AMP-activated protein kinase

Cancer prevention research (Philadelphia, Pa.), 2009-04, Vol.2 (4), p.301-309

2009

Volltextzugriff (PDF)

The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention

Cancer epidemiology, biomarkers & prevention, 2007-07, Vol.16 (7), p.1330-1340

2007

Volltextzugriff (PDF)

Is Inducible Nitric Oxide Synthase a Target for Chemoprevention?

Molecular cancer therapeutics, 2003-08, Vol.2 (8), p.815

2003

Volltextzugriff (PDF)

The epigenome as a target for cancer chemoprevention

JNCI : Journal of the National Cancer Institute, 2003-12, Vol.95 (23), p.1747-1757

2003

Volltextzugriff (PDF)

The National Cancer Institute’s PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets

Seminars in oncology, 2016-02, Vol.43 (1), p.189-197

2016

Volltextzugriff (PDF)

Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents

Molecular cancer therapeutics, 2002-03, Vol.1 (5), p.357

2002

Volltextzugriff (PDF)

Targeting epigenetic regulatory mechanisms in cancer chemoprevention

Expert opinion on therapeutic targets, 2005-04, Vol.9 (2), p.315-328

2005

Volltextzugriff (PDF)

Mechanistic considerations in chemopreventive drug development

Journal of cellular biochemistry, 1994, Vol.56 (S20), p.1-24

1994

Volltextzugriff (PDF)

The NCI’s PREVENT Cancer Preclinical Drug Development Program: Overview, Current Projects, Animal Models, Agent Development Strategies, and Molecular Targets

Seminars in oncology, 2015-09, Vol.43 (1), p.189-197

2015

Volltextzugriff (PDF)

Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives

Cancer epidemiology, biomarkers & prevention, 1996-08, Vol.5 (8), p.657-666

1996

Volltextzugriff (PDF)

Farnesyl protein transferase inhibitors as potential cancer chemopreventives

Cancer epidemiology, biomarkers & prevention, 1997-04, Vol.6 (4), p.267

1997

Volltextzugriff (PDF)

Progress in applied chemoprevention research

Seminars in oncology, 1990-08, Vol.17 (4), p.438-455

1990

Volltextzugriff (PDF)

Flavonoid inhibition of the human neutrophil NADPH-oxidase

Biochemical pharmacology, 1984-04, Vol.33 (8), p.1367-1369

1984

Volltextzugriff (PDF)

Database of inhibitors of carcinogenesis a

Environmental carcinogenesis review, 1988-01, Vol.6 (3), p.7-18

1988

Volltextzugriff (PDF)

Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia

Blood, 2011-09, Vol.118 (9), p.2618-2621

2011

Volltextzugriff (PDF)

Multiphoton imaging and Raman spectroscopy of the bovine vertebral endplate

Analyst (London), 2021-06, Vol.146 (13), p.4242-4253

2021

Volltextzugriff (PDF)

A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)

European urology, 2015-03, Vol.67 (3), p.534-543

2015

Volltextzugriff (PDF)

Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer

JNCI : Journal of the National Cancer Institute, 2016-02, Vol.108 (2), p.1

2016

Volltextzugriff (PDF)

Radiation and Busulfan-Free Hematopoietic Stem Cell Transplantation Using Briquilimab (JSP191) Anti-CD117 Antibody-Conditioning, Transient Immunosuppression and TCRαβ + T-Cell/CD19 + B-Cell Depleted Haploidentical Grafts in Patients with Fanconi Anemia

Blood, 2023-11, Vol.142 (Supplement 1), p.229-229

2023

Volltextzugriff (PDF)

Blazing a trail for the clinical use of rapamycin as a geroprotecTOR

GeroScience, 2023-10, Vol.45 (5), p.2769-2783

2023

Volltextzugriff (PDF)

Creating a Blueprint of Well-Being in Oncology: An Approach for Addressing Burnout From ASCO’s Clinician Well-Being Taskforce

American Society of Clinical Oncology educational book, 2021-06 (41), p.e339-e353

2021

Volltextzugriff (PDF)

Standard PREanalytical Code Version 3.0

Biopreservation and biobanking, 2018-02, Vol.16 (1), p.9-12

2018

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(45)
Bücher
(1)
Reviews
(1)

Sprache

Englisch
(47)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(27)
Humans
(23)
Oncology
(12)
Animals
(10)
Biological And Medical Sciences
(9)
Male
(9)
Medical Sciences
(9)
Neoplasms - Prevention & Control
(9)
Chemoprevention
(7)
Female
(7)
Cancer
(6)
Adolescent
(4)
Anticarcinogenic Agents - Pharmacology
(4)
Cell Biology
(4)
Child, Preschool
(4)
Hematologic And Hematopoietic Diseases
(4)
Infant
(4)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(4)
Neoplasms - Metabolism
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting the AKT protein kinase for cancer chemoprevention

Energy homeostasis and cancer prevention: the AMP-activated protein kinase

The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention

Is Inducible Nitric Oxide Synthase a Target for Chemoprevention?

The epigenome as a target for cancer chemoprevention

The National Cancer Institute’s PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets

Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents

Targeting epigenetic regulatory mechanisms in cancer chemoprevention

Mechanistic considerations in chemopreventive drug development

The NCI’s PREVENT Cancer Preclinical Drug Development Program: Overview, Current Projects, Animal Models, Agent Development Strategies, and Molecular Targets

Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives

Farnesyl protein transferase inhibitors as potential cancer chemopreventives

Progress in applied chemoprevention research

Flavonoid inhibition of the human neutrophil NADPH-oxidase

Database of inhibitors of carcinogenesis a

Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia

Multiphoton imaging and Raman spectroscopy of the bovine vertebral endplate

Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units

A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)

Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer

Radiation and Busulfan-Free Hematopoietic Stem Cell Transplantation Using Briquilimab (JSP191) Anti-CD117 Antibody-Conditioning, Transient Immunosuppression and TCRαβ + T-Cell/CD19 + B-Cell Depleted Haploidentical Grafts in Patients with Fanconi Anemia

Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency Virus

Blazing a trail for the clinical use of rapamycin as a geroprotecTOR

Creating a Blueprint of Well-Being in Oncology: An Approach for Addressing Burnout From ASCO’s Clinician Well-Being Taskforce

Standard PREanalytical Code Version 3.0

Suchergebnisse filtern